At this point, every AbbVie investor knows about the company's reliance on its blockbuster drug Humira. The drug accounts for around half of the company's total sales and was one of its main growth drivers last quarter. While most investors are wondering what will happen to this drug's sales after it loses patent protection in 2016, some may forget that the company has other drugs that are poised to lose market exclusivity in the coming years. In the following segment, health care analysts David Williamson and Max Macaluso discuss the upcoming patent expirations that AbbVie investors need to watch.
More Compelling Companies
One of the best parts of owning big pharma stocks like AbbVie is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The relevant video segment can be found between 5:10 and 6:59.
The article Patent Expirations AbbVie Investors Need to Watch originally appeared on Fool.com.
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.